Home | Business News | Browse by Publication | M | M2 Presswire

CNS Drug Discoveries: Schizophrenia Chapter Answers Questions Such As What % Of The Market Will Be Taken By Generics In 2014?

Article Excerpt
M2 PRESSWIRE-29 August 2008-Research and Markets: CNS Drug Discoveries: Schizophrenia Chapter Answers Questions Such As What % Of The Market Will Be Taken By Generics In 2014?(C)1994-2008 M2 COMMUNICATIONS LTD

RDATE:01092008

Dublin - Research and Markets (http://www.researchandmarkets.com/research/3a53d8/cns_drug_discoveri) has announced the addition of the "CNS Drug Discoveries: Schizophrenia Chapter" report to their offering.

This chapter of CNS Drug Discoveries focuses on the schizophrenia market.

The antipsychotic market generated global sales of US$19.6 billion, accounting for 21% of global CNS sales in 2007. While atypical antipsychotics now account for over 80% of global sales, concerns over safety are leading to a slow down in growth.

The market is ready for the launch of the third-generation atypical antipsychotics which may offer improved tolerability and may not be associated with extrapyramidal symptoms, cardiotoxicity, weight gain or detrimental metabolic changes. Two products have recently been launched, with four in late-stage clinical development: these could be tomorrow s leading brands if they have improved tolerability and safety profiles.

Meanwhile, companies which market today s leading brands continue to optimise their drugs life-cycles pursuing new formulations (intramuscular, slow release) to aid compliance, new indications (major depression, anxiety disorders, autism, maintenance of bipolar disorder) and to initiate additional Phase IV trials to optimise and educate the community regarding the courses of treatment.

Importantly, many of these products have been available...